National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 77875 [2024-21736]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 185 / Tuesday, September 24, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; HIV
COMORBIDITIES AND RESERVOIRS.
Date: November 8, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
NIDDK, Democracy II, Suite 7000A, 6707
Democracy Boulevard, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Maria E. Davila-Bloom,
Ph.D., Scientific Review Officer, National
Institute of Diabetes and Digestive and
Kidney Diseases, National Institutes of
Health, 6707 Democracy Boulevard, Rm.
7017, Bethesda, MD 20892–5452, (301) 594–
7637, davila-bloomm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
mail.nih.gov. Licensing information
may be obtained by communicating
with the Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Rockville,
MD 20852: tel. 301–496–2644. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished information related to the
invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of Support for Research
Excellence (SuRE) Program and Support for
Research Excellence—First Independent
Research (SuRE-First) Award (R16).
Date: October 31–November 1, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of General Medical
Sciences, Natcher Building, 45 Center Drive,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Person: John J. Laffan, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health,
Natcher Building, 45 Center Drive, Room
3AN18J, Bethesda, Maryland 20892, 301–
594–2773, laffanjo@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Monoclonal Antibodies That Bind to
the Underside of Influenza Viral
Neuraminidase
Dated: September 18, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–21740 Filed 9–23–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Dated: September 18, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
Government-Owned Inventions;
Availability for Licensing
[FR Doc. 2024–21736 Filed 9–23–24; 8:45 am]
ACTION:
AGENCY:
National Institutes of Health,
HHS.
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Haiqing Li at 240–627–3708, or lihai@
SUMMARY:
lotter on DSK11XQN23PROD with NOTICES1
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
VerDate Sep<11>2014
18:46 Sep 23, 2024
Jkt 262001
PO 00000
Frm 00065
Fmt 4703
Description of Technology
Current influenza vaccines mainly
induce antibodies against the surface
glycoprotein hemagglutinin (HA) that
block viral attachment to its host
receptors and viral membrane fusion to
the host cell. The immunodominant
head region of HA undergoes antigenic
drift and antibodies directed to the head
confer little cross-protections between
strains or subtypes.
Researchers at the Vaccine Research
Center of the National Institute of
Allergy and Infectious Diseases have
identified human monoclonal
antibodies that each bind distinct
epitopes on the less abundant yet
critical viral surface glycoprotein
neuraminidase (NA). These antibodies,
isolated from convalescent individuals
with confirmed influenza A H3N2
infection, inhibit viral propagation of a
wide range of human H3N2, swineorigin variant H3N2, and H2N2 viruses
and confer pre-exposure and postexposure protection from lethal H3N2
infection in mice. Cryo-electron
microscopy revealed that two of these
antibodies bind non-overlapping
epitopes covering the underside of the
NA head, thus defining a potential
vaccine target.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404.
Potential Commercial Applications
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
77875
Sfmt 4703
• Prevention or treatment of influenza
infection
• Testing influenza antigens
Competitive Advantages
• Improved breadth of protection
relative to influenza HA-targeting
antibodies
Development Stage: Preclinical.
Inventors: Masaru Kanekiyo (NIAID),
Sarah Andrews (NIAID), Julia
Lederhofer (NIAID), Yaroslav Tsybovsky
(Leidos Biomedical Research).
E:\FR\FM\24SEN1.SGM
24SEN1
]]>Agencies
[Federal Register Volume 89, Number 185 (Tuesday, September 24, 2024)]
[Notices]
[Page 77875]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21736]
[[Page 77875]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; HIV COMORBIDITIES AND
RESERVOIRS.
Date: November 8, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, NIDDK, Democracy II, Suite
7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Maria E. Davila-Bloom, Ph.D., Scientific Review
Officer, National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health, 6707 Democracy Boulevard,
Rm. 7017, Bethesda, MD 20892-5452, (301) 594-7637, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: September 18, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-21736 Filed 9-23-24; 8:45 am]
BILLING CODE 4140-01-P
